Steroid-refractory Acute Graft Versus Host Disease Clinical Trial
Official title:
A Single-arm, Multi-center Study of Ruxolitinib for the Treatment of Chinese Patients With Grade II-IV Corticosteroid-refractory Acute Graft Versus Host Disease
The purpose of this study is to assess the efficacy and safety of ruxolitinib therapy in Chinese adults and adolescents (≥ 12 years old) with Grade II-IV steroid-refractory acute graft versus host disease (SR-aGvHD).
Participants will start with a screening period to assess the eligibility; only participants who meet all the inclusion and none of the exclusion criteria will start study treatment from Day 1 to Week 24 or end of treatment. Following safety follow up visits, participants will receive the long-term follow-up until Month 12. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04128319 -
T-Guard as Treatment for Steroid Refractory Acute GVHD (BMT CTN 1802)
|
Phase 3 | |
| Terminated |
NCT04934670 -
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
|
Phase 3 |